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Adequate hematopoietic stem cell (HSC) mobilization and collection is required prior to proceeding with high
dose chemotherapy and autologous hematopoietic stem cell transplant. Cytokines such as G-CSF, GM-CSF, and
peg-ﬁlgrastim, alone or in combination with plerixafor, and after chemotherapy have been used to mobilize
HSCs. Studies have shown that the efﬁciency of HSC mobilization and collection may vary when different
methods of mobilization are used. No studies have shown that survival is signiﬁcantly affected by the method
of mobilization, but some studies have suggested that cost and resource utilization may be different between
different mobilization techniques. After the FDA approval of plerixafor with G-CSF to mobilize HSCs many
transplant centers became concerned about the cost of HSC mobilization. A panel of experts was convened
ant this paper reviews the current literature on the pharmacoeconomics of HSC mobilization.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by hematopoietic
stem cell rescue is a frequently used strategy in the treat-
ment of hematological malignancies. Autologous hemato-
poietic stem cell transplantation (aHSCT) is used routinely in
the treatment of relapsed non-Hodgkin lymphoma (NHL)
and Hodgkin’s lymphoma [1-3], and it has been shown to
improve both depth of response and overall survival in
patients with multiple myeloma (MM) [4-11]. The ability to
improve patient outcomes with aHSCT is directly dependent,
however, on successful mobilization and collection of stem
cells. Historically, stem cell mobilization options have been
limited to either growth factors alone or chemotherapy in
combination with growth factors [12]. Granulocyte colony-
stimulating factor (ﬁlgrastim, G-CSF) and granulocyte
macrophage colony-stimulating factor (sargramostim, GM-
CSF) are US Food and Drug Administration (FDA)-approved
for hematopoietic stem cell (HSC) mobilization [12]. Che-
momobilization (CM) regimens often include agents, such as
cyclophosphamide, etoposide, or cytarabine, and may
incorporate rituximab for lymphoma patients. A CM strategy
may be chosen over growth factors alone in an effort to
produce higher stem cell yield or reduce tumor burden anddgments on page 1307.
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[13,14].
In this paper, we review the current literature on the
pharmacoeconomics of mobilization in HSCT. Our goals are
to summarize economic evaluations to date with an
emphasis on the issues that are somewhat unique to
outcomes studies of HSCT and to better understand the value
of recent developments in HSCT, particularly plerixafor. First,
we provide an overview of the literature on the clinical and
economic outcomes associated with traditional mobilization
strategies. Second, we examine the pharmacoeconomic
evidence on novel mobilization approaches, focusing on the
novel agent plerixafor. This is accompanied by a general
overview of methods used in economic evaluations of
healthcare interventions, followed by a discussion of the
limitations of the current literature and suggestions for
future studies.
Standard Mobilization Costs
The costs and consequences associated with traditional
mobilization strategies vary. Over the past 15 years, reported
costs of mobilization with growth factors alone have ranged
from approximately $6000 up to $20,000 per patient [15-18].
When CM is used as a stand-alone cycle apart from standard
induction or salvage therapy, this results in additional
expenses for chemotherapy, hospitalization for chemo-
therapy administration, and management of chemotherapy-
related complications, including febrile neutropenia. Costs
with this approach are therefore higher, with reports rangingTransplantation.
Table 1
Costs and Consequences of Suboptimal Mobilization [25,44]
Consequence Outcome
Failure to mobilize a
sufﬁcient number of
CD34þ cells
 Ineligibility for transplantation and
subsequent relapse
 Increased apheresis days
 Need for bone marrow harvest
 Added cost of remobilization attempts
 Increased resource utilization
Transplantation with
suboptimal apheresis
product
 Delayed, partial, or failed engraftment
 Prolonged hospitalization and increased
hospitalization costs
 Increased infections
 Increased bleeding or need for
transfusions
Unmeasured costs to
patient/caregiver
 Transportation to/from apheresis center
 Cost of housing/sustenance
 Psychological strain
 Missed work time
Unmeasured costs
to center
 Weekend apheresis
 Delay in treatment
 Disruption of patient ﬂow
 Inability to proceed to transplantation
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regimen [19-21]. CM readmission rates at some centers have
been reported to be 20% to 26%, and the additional hospi-
talization generates $7000 to $10,000 in increased costs
[19,20,22]. A recent cost analysis of CM demonstrated that
this approach is associated with an 80% chance of a nonideal
outcome (ie, collections below target, additional apheresis
sessions, and complications), which was, in turn, associated
with higher mobilization costs [19]. Other disadvantages of
CM include the unpredictability of the apheresis schedule,
increased costs to patients and caregivers by missed work,
frequent clinic visits and admissions, and housing costs
[23,24]. Much of these increased costs associated with CM
are abrogated by mobilizing stem cells after a planned cycle
of chemotherapy rather than administering CM as a stand-
alone regimen, although this approach will not eliminate
unpredictable apheresis scheduling. One multicenter retro-
spective review found that, in addition to an increase in
apheresis costs of nearly $3000 per patient, CM resulted in
increased weekend apheresis, with 12.6% of patients begin-
ning apheresis on a Thursday or Friday, and 13.3% beginning
on a weekend [24].
The advantages of CM include providing standard salvage
therapy for relapsed NHL or Hodgkin’s Disease patients and
greater CD34þ cell collections compared to cytokine-only
mobilization. However, no studies to date have shown any
difference between CM and cytokine-only mobilization in
the amount of tumor contamination of the stem cell product
and transplantation outcomes, such as engraftment and
survival.
Costs Associated with Poor Mobilization/Failure to
Mobilize
Various patient-related and disease-related characteris-
tics have been identiﬁed as having a negative impact on
mobilization success rates. These include advanced age
[25-27]; diagnosis of NHL [25]; prior radiation therapy,
extensive prior chemotherapy, or prior treatment with
lenalidomide or purine analogs [26-38]; a hypocellular
marrow, marrow involvement at diagnosis, low platelet
count, and refractory disease [25]; and prior mobilization
failure. Historical failure rates with traditional mobilization
approaches have been reported to be as high as 18% to 38%
[18,39-42], although more recent studies consistently show
mobilization failure rates to be below 15% in patients with
up-frontetreated MM [43-45] and below 10% when CM is
incorporated into planned chemotherapy cycles for patients
with NHL [46-48]. For those patients who do fail initial
mobilization attempts, however, remobilization failures
reach 77% [39].
In addition to being potentially unsuccessful, remobili-
zation attempts are expensive. Standard remobilization
strategies include dose-escalated G-CSF [49-51], G-CSF plus
GM-CSF (G þ GM) [52-54], and CM [27]. In 2004, G þ GM
remobilization was estimated to cost $5900 per patient,
whereas remobilization with G-CSF alone averaged $9000
per patient [55]. A recent cost assessment of CM remobili-
zation of MM patients with hyper-cyclophosphamide,
vincristine, adiamycin, and dexamethasone chemotherapy
followed byG-CSFwas shown to be $45,000 per patient, with
37.5% of those incurring an additional $13,000 in charges for
hospital readmissions [20]. Poor mobilization is associated
not only with an increase in cost, but also escalated resource
consumption, including increased growth factor, antibiotic,
and transfusion support; more frequent hospitalization;more apheresis procedures; and delayed engraftment
[19,42]. Table 1 summarizes the costs and consequences of
poor mobilization.
Options are limited for those patients who fail to col-
lect sufﬁcient stem cells for transplantation on multiple
mobilization attempts. Bonemarrow harvest and subsequent
autologous bone marrow transplantation (BMT) add con-
siderable cost and are associated with more complications
than peripheral blood stem cell transplantation (PBSCT). The
cost of the harvest procedure itself ranges from nearly $5000
to $8500 [15,56,57], and early comparisons of autologous
BMT to PBSCT showed an average 20% to 30% increase in total
transplantation costs with BMT [15,56,58]. BMT has also
been associated with poorer engraftment and reduced
quality of life (QoL) when compared with PBSCT [58]. Allo-
geneic stem cell transplantation may be an option in select
patients who fail multiple mobilization attempts, but it is
associated with increased morbidity and mortality and is not
available to all patients because of lack of a suitable donor.
For these patients, further treatment options become limited
to salvage or maintenance chemotherapy without trans-
plantation, which may be associated with increased risk of
relapse.Novel Mobilization Approaches
In 2008, the novel agent plerixafor, a CXCR4 chemokine
receptor antagonist, was approved for use by the FDA in the
United States. Plerixafor is indicated for ﬁrst-line mobiliza-
tion of hematopoietic stem cells into the peripheral blood for
collection and subsequent autologous transplantation in
patients with NHL and MM. Several studies, including the
initial phase III trials of plerixafor and G-CSF compared with
G-CSF and placebo, have demonstrated that plerixafor can
overcome some of the known risk factors for poor stem cell
mobilization [26,43,59-61], and may reduce overall mobili-
zation failure rates from as high as 30% to <10% [16,21,62-
68]. Unfortunately, the acquisition cost of plerixafor has
limited its use in up-front mobilization despite the FDA
indication, as expensive agents within institutions are often
restricted because of budget constraints. In such situations,
pharmacoeconomic (PE) analysis methods are essential to
determine if the superior effectiveness warrants the higher
price.
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Analysis
The purpose of a PE evaluation is to analyze the costs
and consequences of a health intervention and its impact
on individuals, healthcare systems, and even society at
large. A PE evaluation can be conducted from various
perspectives, such as from the industry, payer, institution,
patient, or from society in general. Types of economic
evaluation methods include cost-minimization analysis;
cost-effectiveness analysis; cost-utility analysis; cost-beneﬁt
analysis; and cost-consequence analysis [69]. Although
detailed discussion of these methods is beyond the purview
of this article, the purpose and limitations of a few are
discussed below.
PE analysis methods, in general, have limitations. It is not
within the scope of a single PE analysis to account for all
possible perspectives and outcomes (eg, monetary cost,
economic beneﬁt, effectiveness, utility); rather, investigators
must choose those that are most relevant and discern which
PE analysis method is best suited to assess those outcomes.
Cost-utility analysis is considered the gold standard in PE
evaluations [70,71], because it facilitates comparisons of the
cost-effectiveness of interventions across health care using
a common metricdcost per quality adjusted life-year
(QALY). This approach, however, is challenging and often
criticized on a variety of levels: methods for determining
health-related QoL may be cumbersome, controversial, or
lack sensitivity in certain diseases or conditions; all possible
beneﬁts of an intervention may not be accounted for by the
QoL index; and it assigns equal value to all QALYs without
accounting for social factors, such as severity of illness, age,
or socioeconomic status of the individual [72]. Furthermore,
although QoL is an important endpoint for physicians,
patients, and society at large, it may not be valued as much
by administrators or payers whose focus is budget impact;
therefore, QALY may not be an appropriate method for
evaluating complex interventions, such as those involving
cancer treatment or end-of-life care [73].
A decision-analytic model is another health economic
outcomes research tool that synthesizes data from real-
world patients to model a disease, treatment, and outcome
process; microsimulation assigns a probability to each
possible event as patients move through a series of treat-
ment cycles. It should be noted, however, that models are
only as useful as the data onwhich they are based, and small
patient populations will result in larger standard of error. A
useful model incorporates many parameters, requiring
extensive data best collected in a prospective manner.
Further challengeswithPE research liewithin thepractical
execution of these studies. Costs, patient populations, and
standard of care often vary by institution or region, so that
data obtained from a single-center PE analysis may not be
applicable to a national or international audience. In addition,
medical centers are often reluctant to share proprietary
contract and budget information with other centers, and
publishing institution-speciﬁc PE data in the public domain
may be frowned upon by administrators. This presents
a particular challenge when attempting to conduct a multi-
center PE evaluationwithmore universally applicable results.
Although PE analyses involve assumptions and have
limitations, they are indispensable to understanding value of
novel therapies that have a high acquisition cost and
substantial budget impact for payers and institutions. For
expensive novel therapies that may be more effective than
the standard of care, it becomes necessary to determine if thesuperior effectiveness of the drug outweighs the increased
cost. For these reasons, various analyses of plerixafor-
containing mobilization regimens have been performed to
determine the effectiveness, net costs, and beneﬁts of pler-
ixafor use compared to standard mobilization regimens
[18,21,62,63,74-78].
PHARMACOECONOMIC ANALYSES OF NOVEL
MOBILIZATION REGIMENS
Up-front Plerixafor
In 2011, Shaughnessy et al. published a retrospective
comparison of 34 MM and lymphoma patients who were
mobilized up front with plerixafor plus G-CSF (PþG) to
a similar number of matched historical controls who were
mobilized with cyclophosphamide and G-CSF (CMþG)
(Table 2) [21]. Data were taken from 2 institutions that
participated in the plerixafor expanded access program.
Historical controls were matched for age, sex, disease, stage,
and number of prior therapies. The analysis compared
effectiveness, cost, resource utilization, and clinical outcomes
of PþG to CMþG. Costs of mobilization failure were not
included in the analysis. Costs were estimated based on
median Centers for Medicare and Medicaid Services national
reimbursement rates and average medication sale prices.
Both approaches yielded 100% successful mobilization
rates, deﬁned in this study as a minimum collection of
2  106 CD34þ cells/kg, although signiﬁcantly more patients
collected an optimal target of at least 5  106 CD34þ cells/kg
[79] in the PþG arm (94% versus 76%, P ¼ .04). Similar
median total CD34þ cells/kg were collected: 0.7  106 with
PþG versus 11.6  106 with CMþG (P ¼ .5). Mean total cost
per patient with PþG was $20,298 versus $19,173 per CMþG
patient (P ¼ .57). PþG had a substantial impact on resource
utilization, with 64% of PþG patients completing apheresis in
1 day compared to 39% of control patients. In addition, PþG
patients received fewer doses of G-CSF, required fewer
hospitalizations and transfusions, and had more predictable
apheresis schedules.
Kymes et al. performed a cost-utility evaluation of G alone
versus PþG as ﬁrst-line mobilization, with data from
Washington University that included patients who partici-
pated in the NHL Phase III plerixafor trial [78]. Data from 20
patients with diffuse large B cell lymphoma who underwent
aHSCT (10 who received G-CSF alone, and 10 who received
PþG) served as the basis for a Markov decision analytic
model that replicated the process of stem cell mobilization,
apheresis, and transplantation. The microsimulation calcu-
lated QALYs for patients who received the 2 mobilization
approaches, and estimated the incremental cost-utility ratio
(ICUR) over the patients’ remaining lifetimes. An ICUR can be
deﬁned as the cost adding of 1 year of perfect health to
a patient’s life with a given treatment. The authors assumed
a conservative ICUR of less than $50,000/QALY to determine
cost-effectiveness, based on a non-US insurance policy
maker’s willingness to pay for a treatment (ie, an insurance
company will pay for a medical intervention if it costs
<$50,000/QALY).
Based on the microsimulation, the expected lifetime cost
of care for diffuse large B cell lymphoma patients who
underwent aHSCT was $93,180 if they were mobilized with
PþG compared with $67,730 with G alone. However, GþP
resulted in 1.75 more QALYs than G alone, which gave an
ICUR for PþG of only $14,574/QALY, well within the range
considered cost-effective by most insurance providers.
Figure 1 is the net beneﬁt acceptability curve from this study,
Table 2
Overview of Pharmacoeconomic Evaluations of Plerixafor for Stem Cell Mobilization
Author Design Mobilization
Regimen (N)
Outcomes
Measured
Costs Assessed Results
Shaughnessy
[21]
Retrospective historical
comparison (of
prospectively collected
data)
PþG (33)
CMþG (33)
CD34þ cell yield
Apheresis days/
scheduling
GCSF doses
Hospital days
Transfusions
Pre-apheresis
Chemotherapy
Drug (P, G, abx)
Hospitalization
Transfusions
Laboratory
Peri-apheresis
Apheresis
CD34þ studies
Storage costs
Successful mobilization 100%
both cohorts, similar cell doses
collected
Mean total cost per patient:
PþG $20,298
CMþG $19,173
(P ¼ NS)
PþG: fewer G doses,
hospitalizations, transfusions,
weekend apheresis
Kymes [78] Retrospective decision
analytic model (of
prospectively collected
data)
G alone (10)
PþG (10)
QALY Drug (P, G)
Apheresis
Storage
Transplantation
Hospitalization
GþP resulted in 1.75 more
QALYs than G alone
ICUR for PþG $14,574/QALY
Vishnu [62] Prospective efﬁcacy and
cost-beneﬁt analysis
Pre-emptive P
G alone (18)
PEPþG (24)
CD34þ cell yield
Apheresis days
Adverse events
ANC/platelet
engraftment
Drug (P, G)
Stem cell collection
Lost revenue
Overall mobilization success
95% (compared to historical
control of 75% before PEP)
Estimated cost savings with
PEP: $19,300 per patient
Li [63] Retrospective comparison/
cost analysis of patient
cohorts pre- and post-P
approval
Post-P approval:
PEPþG (poor
mobilizers, 41)
UPþG (high risk
for FTM, 23)
GCM (good
mobilizers, 124)
Pre-P approval (GCM):
Poor mobilizers (36)
Good mobilizers (112)
Peripheral CD34þ
counts
CD34þ cell yield
ANC/platelet
engraftment
Drug (P, G)
Apheresis
Storage costs
Successful collections:
Poor mobilizers w/PEP 93%
Poor mobilizers w/o PEP 72%
High risk w/UPþG 96%
Good mobilizers pre-/post-P 100%
Estimated costs:
Poor mobilizers w/PEP $30,264
Poor mobilizers w/o PEP $27,796
High risk w/UPþG $20,761
Good mobilizers post-P $15,299
Good mobilizers pre-P $13,550
Campen [74] Retrospective decision
analytic model
PþG (8)
CM þ G (34)
CD34þ cell yield Drug
Laboratory
Apheresis
PþG more effective, less costly
in 69.9% of cases
Adel [75] Retrospective cost
analysis
PþG (35)
CMþG (98)
CD34þ cell yield
Hospital days
Apheresis days
Chemotherapy
Drug (P, G)
Laboratory
Apheresis
Hospitalizations
Second mobilization
PþG associated with fewer
hospital days, fewer apheresis
days, and fewer
mobilization failures
Cost of CM 1.6 times higher
than PþG
Isola [76] Retrospective historical
comparison
G alone (25)
PþG (25)
CD34þ cell yield
GCSF doses
Apheresis days
ANC engraftment
Hospital days post-
transplantation
Drugs
Transfusions
Hospitalization
Apheresis
PþG higher CD34þ cell yield, fewer
apheresis days
G alone had earlier neutrophil
engraftment by 1 day
Hospitalization days similar
Cost of apheresis þ hospitalization:
PþG $61,632
G alone $62,949
(P ¼ NS)
Perkins [77] Retrospective resource
utilization analysis of
second mobilization
PþG (38)
Other [G, CM,
GþGM] (58)
CD34þ cell yield
Apheresis days
Laboratory
Hospital days
Transfusions
IV antibiotics
Clinic visits
NA PþG higher CD34þ cell yield, and
reduced apheresis and
hospitalization requirements
Roberts [18] Retrospective cost-
effectiveness analysis
G alone (115)
CMþG (97)
UP (18)
PEP (63)
CD34þ cell yield Total costs of
successes and
failures
Successful collections/total costs:
G alone 61.9%/$23,044
CMþG 70.1%/$20,736
UP 61.6%/$31,060
PEP 76.2%/$25,460
ANC indicates absolute neutrophil count; abx, antibiotics; CM, chemotherapy mobilization; FTM, failure to mobilize; G, granulocyte colony-stimulating factor;
GM, granulocyte macrophage colony-stimulating factor; ICUR, incremental cost-utility ratio; IV, intravenous; P, plerixafor; PEP, pre-emptive plerixafor;
pt, patient; QALY, quality-adjusted life years; NS, not signiﬁcant; SC, stem cell; w/, with; w/o, without; UP, upfront plerixafor.
P. Shaughnessy et al. / Biol Blood Marrow Transplant 19 (2013) 1301e13091304demonstrating that G alone would be the preferred regimen
only if a decision maker’s willingness to pay was below
$10,000/QALY.
Pre-emptive Plerixafor
Some centers have developed algorithms for pre-emptive
plerixafor use, in which patients receive traditionalmobilization regimens with the addition of plerixafor as
needed to salvage those who have mobilized poorly. Various
PE assessments of these algorithms have been published
(Table 3).
Vishnu et al. from the Mayo Clinic in Florida conducted
a prospective, single-center efﬁcacy and cost-beneﬁt analysis
of a pre-emptive plerixafor mobilization approach in NHL
Figure 1. Net beneﬁt acceptability curve for granulocyte colony-stimulating
factor (G-CSF) versus G-CSF þ plerixafor based on Markov model by Kymes
et al. [78]. The steep G-CSF þ plerixafor curve indicates that its relative
effectiveness is greater than G-CSF alone at a willingness to pay of w$14,500
quality adjusted life-year (QALY), and it is very stable at a willingness to pay of
$36,000/QALY or more. Reprinted with permission.
P. Shaughnessy et al. / Biol Blood Marrow Transplant 19 (2013) 1301e1309 1305and MM patients at high risk for failure [62]. In this trial,
plerixafor was added to G-CSFeonlymobilization if the day 4
peripheral blood CD34þ (PB CD34þ) cell count was below
10 cells/mL and apheresis began on day 5. Of the 42 patients
mobilized with this approach, 24 (57%) required the addition
of plerixafor on day 4. The overall mobilization success rate
was 95% compared with a historical success rate of only 75%
before the institution of the pre-emptive strategy. By
adjusting for revenue losses incurred when 25% of patients
mobilized with G-CSF alone do not proceed to trans-
plantation, they estimated a cost savings of $19,300 per
patient with the use of the pre-emptive plerixafor approach.
Li et al. from Emory University conducted a single-center
retrospective historical comparison of NHL and MM patients
mobilized with a pre-emptive plerixafor strategy to patients
mobilized at their center before plerixafor approval [63]. The
pre-approval cohort included 36 poor mobilizers (deﬁned as
patients with a PB CD34þ cell count of <15 cells/mL and
a WBC >10  109/L after at least 5 days of G-CSF) and 112
good mobilizers who received either CMþG or G-CSF alone
as their mobilization regimen. The postapproval cohort
included 124 good mobilizers who received only G-CSF with
or without chemotherapy and 64 patients thought to be at
risk for poor mobilization. Of these, 23 were high-risk
patients who received scheduled PþG based on a previous
failed mobilization attempt, prior lenalidomide therapy, or
refractory disease with multiple prior treatment regimens
and 41 poor mobilizers who received pre-emptive plerixafor
plus G-CSF. Among the poor mobilizers, those who received
pre-emptive plerixafor had a successful collection rate of 93%
compared with 72% in the historical control group; high-risk
patients who received scheduled PþG had a successful
mobilization rate of 96%. Estimated mobilization costs were
similar in the poor mobilizer group regardless of plerixafor
use ($30,264 for those receiving plerixafor compared with
$27,796 for the historical controls), lower in the high-risk
patients who received scheduled PþG ($20,761), and
lowest in the good mobilizer cohorts ($15,299 in the post-
plerixafor phase, $13,550 for the preplerixafor cohort).A recent report of mobilization and resource utilization
outcomes for a risk-based mobilization approach was con-
ducted by Abhyankar et al. [65]. In their algorithm, plerixafor
was instituted in patients whose day 5 PB CD34þ cell count
was suboptimal for the target collection goal or in patients
whose apheresis day 1 CD34þ cell yield was less than 50% of
the desired collection. A total of 159 patients who underwent
aHSCT for various diagnoses were mobilized with G-CSF; of
those, 55 required the addition of plerixafor based on the
stated criteria. Target collection was attained in 151 patients
(95%) compared with only 81% of historical controls. Use of
the plerixafor algorithm had the additional beneﬁt of
reducing apheresis days to 1.7 from 3 in historical controls.
Chen et al. from the Oregon Health Science Center
reviewed 49 consecutive mobilization attempts with G-CSF
alone and determined that a day 4 PB CD34þ cell count of
15 cells/mL correlated with a day 5 collection yield of 2  106
CD34þ cells/kg [80]. The investigators therefore instituted
a clinical guideline to initiate plerixafor in patients whose
day 4 PB CD34þ cell count is between 5 cells/mL and
15 cells/mL, or in thosewho had a poor collection yield during
apheresis. A subsequent prospective analysis of 166 consec-
utive lymphoma and plasma cell dyscrasias patients mobi-
lized with these guidelines demonstrated successful
mobilization rates (deﬁned as collection of 2  106 CD34þ
cells/kg) in 93% patients. Plerixafor was administered to 43%
of eligible mobilization patients according to guideline. The
median cell yield was 4.9  106 CD34þ cells/kg in patients
who received plerixafor, and 6.3  106 CD34þ cells/kg in
those who received only G-CSF, although comparisons could
not be made between the yields because the patients who
received plerixafor plus G-CSF were already predicted to be
a group of patients whowould notmobilizewell. Themedian
number of apheresis days and failure rates in both groups
were similar. These data demonstrated that implementation
of a clinical pathway based on their patient subset was highly
effective in ensuring access to plerixafor and maximizing the
collection and minimizing mobilization failures in a very
simple manner.
Costa et al. developed an algorithmic approach to hema-
topoietic stem cell mobilization to determine those patients
who would most beneﬁt from the addition of plerixafor to
G-CSF [66]. Mathematical equations were developed that
incorporated both the target CD34þ cell collection for a given
patient and the patient’s day 4 PB CD34þ cell count. The
equations estimated the costs of proceeding beyond day 4 of
mobilization with G-CSF alone versus proceeding with the
addition of plerixafor, and accounted for the costs of drug
(plerixafor, G-CSF), apheresis, and stem cell storage. For each
target CD34þ cell yield (3  106 CD34þ cells/kg if a single
transplantation was planned, 6  106 for tandem trans-
plantation), investigators determined the day 4 PB CD34þ
cell count values at which proceeding with G alone would be
more costly than proceeding with PþG. These values then
became the threshold for institution of plerixafor. For
example, if the target collection was 3  106 CD34þ cells/kg
and the day 4 PB CD34þ cell count was below 14 cells/mL,
plerixafor was started on day 4. The algorithm was
prospectively validated with a cohort of 34 lymphoma and
MMpatients, where 97% of patients reached target collection
and 94% completed apheresis within the predicted number
of days. The median projected savings with G-CSF alone in
good mobilizers (over the use of up-front plerixafor in all-
comers) was $2589 per patient.
Table 3
Overview of Risk-Adapted Algorithms for Plerixafor Use in Stem Cell Mobilization
Study N Mobilization
Regimens (N)
Target CD34þ/kg
Cell Yield
Criteria for P Costs Assessed Outcomes
Vishnu [62] 42 PEP
G alone (18)
PþG (24)
2  106
(minimum)
D4 PB CD34þ <10 cells/mL Drug (P, G)
SC collection
Lost revenue
95% reached minimum collection
Li [63] 165 PEP
G þ/ CM (124)
PþG þ/ CM (41)
2  106
(minimum)
PB CD34þ <15 cells/mL and
WBC >10  109/L after
5 days of GCSF
Drug (P, G)
Apheresis
Storage
98% reached minimum collection
Costa [66] 34 PEP
G alone (11)
PþG (23)
6  106
(some MM)
3  106
(all others)
Mathematical equation estimating
costs of proceeding w/G alone
versus PþG based on D4 PB CD34þ
Drug (P, G)
Apheresis
Storage
33 of 34 (97%) of patients reached
target collection
94% completed apheresis within
predicted no. of apheresis days
Median projected savings w/G
alone in good mobilizers was
$2589/patient
Costa [67] 131 PEP
G-alone (16)
PþG (33)
Failed to
complete (1)
versus
CMþG (81)
6  106
(some mm)
3  106
(all others)
Mathematical equation estimating
costs of proceeding w/G alone
versus P3G based on D4 PB CD34þ
Chemotherapy
Drug (P, G)
Apheresis
Storage
FN hospital days
98% of PEP proceeded to aHSCT
versus 77.8% of CM
94% of PEP reached target
collection versus 76.5% of CM
Cost of successful mobilization:
PEP $23,893
CMþG $29,423
Abhyankar
[65]
159 PEP
G alone (104)
PþG (55)
2.5  106
(single)
5  106
(tandem)
D5 PB CD34þ <10 cells/mL:
Administer P, begin apheresis D6
D5 PB CD34þ 10 but <20 cells/mL:
If target is 2.5, begin apheresis
without P; if target is 5, begin
apheresis but administer P that
night.
D5 PB CD34 20:
Begin apheresis without P
Apheresis Day 1 cell yield <50%
desired collection: administer P
None 94.9% of patients reached target
collection (compared to 81%
of historical control data)
PEP reduced apheresis days to
1.7 from 3 in historical controls
Micallef [16] 147 PEP
G alone (80)
PEPþG (55)
UPþG (12)
2  106
(minimum)
Day 5 PB CD34þ <10 cells/mL
or
Daily apheresis yield of
<0.5  106/kg
NA 95% of patients reached target
collection compared with 78%
historical success rate
D4 PB-CD34þ <10 or apheresis
Day 1 yield <1.5 million
predicted >70% patients who
would receive P
Micallef [68] 592 G alone (278)
PEP1þG (216)
PEP2þG (98)
2  106
(minimum)
PEP1
Same as above
PEP2
D4 PB CD34þ <10 (single) or
<20 cells/mL (tandem)
or
Apheresis Day 1 yield <1.5  106/kg
or
Any subsequent daily yield
<0.5  106/kg
Chemotherapy
Drug (P, G)
Apheresis
Storage
Minimum cell collection reached:
G - 81%
PEP1 - 95%
PEP2 - 99%
(P < .001)
Average cost per patient:
G $17,300
PEP1 $21,686
PEP2 $20,695
Shapiro [61] 196 G alone (124)
UPþG (72)
2  106 in 1
apheresis
High-risk patients
Group 1: 3þ lines of prior chemo;
Group 2: 4þ cycles of hyper-CVAD;
Group 3: 4þ cycles of lenalidomide
NA Successful collection rates:
Group 1: 67% UP versus 38% G
Group 2: 47% UP versus 21% G
Group 3: 100% UP versus 39% G
Chen [80] 166 PEP
G alone (56)
PþG:
Low PB CD34þ (62)
Poor yield (10)
Guideline not
followed (36)
2  106
(minimum)
Day 4 PB CD34þ 5 to 15 cells/mL
or
Poor apheresis yield (at physician
discretion)
NA 93% of patients reached
minimum collection
LaPorte [64] 68 PEP
G alone (38)
PþG (30)
4  106
(target)
2  106
(minimum)
Day 4 PB CD34þ <12 cells/mm3
or
Daily apheresis yield of <1  106 or
50% of previous day’s yield
NA 93% of patients reached target
collection
99% of patients reached
minimum collection
aHSCT indicates autologous hematopoietic stem cell transplantation; CM, chemotherapy mobilization; CMþG, chemotherapy mobilization with granulocyte
colony-stimulating factor; D, day; FN, febrile neutropenia; G, granulocyte colony-stimulating factor; MM, multiple myeloma; P, plerixafor; PB CD34þ, peripheral
blood CD34þ cell count; PEP, pre-emptive plerixafor; UP, upfront plerixafor; CVAD, cyclophosphamide, vincristine, adiamycin, and dexamethasone.
P. Shaughnessy et al. / Biol Blood Marrow Transplant 19 (2013) 1301e13091306The outcomes and costs for 50 patients mobilized with
the above algorithm were subsequently compared with a
historical cohort of 81 patients who underwent CM with
G-CSF and GM-CSF [67]. The costs assessed in this analysisincluded chemotherapy, mobilization drug(s), apheresis,
stem cell storage, and hospital days for febrile neutropenia
admission. Thirty-three of 50 patients (66%) in the algorithm
cohort required the addition of plerixafor, and 16 (32%) were
P. Shaughnessy et al. / Biol Blood Marrow Transplant 19 (2013) 1301e1309 1307mobilized with G-CSF alone. A signiﬁcantly higher propor-
tion of patients in the algorithm group were able to proceed
to aHSCT (98%) compared with 77.8% of patients in the CM
cohort, P < .01; 94% of patients mobilized according to the
algorithm reached the target collection compared with 76.5%
of CM patients, and hospital admission rate was signiﬁcantly
lower in this group as well. The cost of successful mobiliza-
tion was less in the algorithm group compared with the CM
group, $23,893 versus $29,423, respectively.
DISCUSSION
Prospective PE data for ﬁrst-line plerixafor-based mobi-
lization are limited. Much of the data needed to create
a useful model are simply missing from existing randomized
controlled trial data, and therefore cannot be incorporated
into retrospective PE evaluations of plerixafor. The resulting
gap in the published literature can only be ﬁlled by a multi-
center, prospective randomized health economic outcomes
research study that should include the various mobilization
strategies for MM and lymphoma patients undergoing
aHSCT. An intent-to-treat approach would include follow-up
of nonmobilizers for a more accurate assessment of
outcomes. Primary endpoints would be QoL and cost, with
secondary endpoints of mobilization and transplantation
outcomes, efﬁciency of the collection process (eg, apheresis
resource utilization), and survival. Standard challenges
facing multicenter PE trials could be avoided to some degree
by using the Medicare allowable resource-based relative
value scale to standardize costs across centers and reduce the
need for disclosure of individual institutional costs.
Center-Speciﬁc Evaluations of Mobilization Strategies
and Costs
Until PE data from larger trials are available, centers are
encouraged to assess their ownmobilization failure rates and
costs to determinewhether other mobilizationmethods may
offer advantages. This can be done using amodiﬁed approach
to health economic research analysis.
Step 1: Deﬁne the problem
Conduct a retrospective assessment of the institution’s
failure rate with current mobilization regimen(s).
Step 2: Identify the appropriate comparators
The institution’s standard of care for mobilization should
be compared to other methods (ie, up-front plerixafor,
algorithms using plerixafor, chemotherapy, etc.).
Step 3: Identify the perspective
For most centers, the perspectives that will have the
greatest impact on regimen choice will be those of the
institution administrators, the healthcare practitioners, and
the patient.
Step 4: Identify outcomes to Be measured
These should include failure rates, drug-related adverse
events, and morbidities, such as infection rates, cytopenias
requiring transfusions, andhospital admissions/readmissions.
Step 5: Identify relevant center-speciﬁc costs of current
mobilization techniques
Assess the costs/charges associated with mobilization
drug(s), apheresis, laboratory monitoring, stem cell pro-
cessing and storage, physician service billing, and hospitali-
zations. The costs of failed mobilization attempts, in additionto those incurred during remobilization, should be included.
In addition to monetary costs, consideration should be given
to resource utilization, such as days of apheresis required.
Step 6: Implement the new approach
Prospectively collect data on costs, resource utilization,
and mobilization outcomes associated with up-front plerix-
afor use.
Step 7: Compare mobilization strategies
After a predetermined number of patients have been
mobilized, compare with the historical cohort mobilized
with the standard regimen. Comparisons should be made
regarding successful collection of predeﬁned minimum and
target cell yields, in addition to overall monetary cost of the
mobilization attempts and resource utilization with each
strategy evaluated.
Although mobilization techniques have not been
shown to alter the clinical outcomes of patients undergoing
aHSCT, available data suggest that effectiveness, QoL, and
costs may differ signiﬁcantly between strategies
[18,19,21,24,62,63,68,74-78]. Prospective studies assessing
QoL and PE endpoints are warranted.
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